Ryan Barbara 4

What Happened Ryan Barbara, a director at MiNK Therapeutics (INKT), was granted restricted stock units (RSUs) as board/committee compensation. The filing reports two awards: 1,629 RSUs on 2026-03-02 at an implied value of $10.90 each (≈ $17,756) and 1,434 RSUs on 2026-06-01 at $12.38 each (≈ $17,753), totaling 3,063 RSUs worth about $35,509. These RSUs represent a contingent right to one share per RSU and are scheduled to vest one month after each grant date. This is an award (compensation), not an open-market purchase or sale.

Key Details

• Transaction type: A (Award/Grant of RSUs)
• Grants:
  • 2026-03-02 — 1,629 RSUs @ $10.90 (value ≈ $17,756)
  • 2026-06-01 — 1,434 RSUs @ $12.38 (value ≈ $17,753)
• Total: 3,063 RSUs, total value ≈ $35,509
• Vesting: Each RSU converts to one share one month after its grant date (per footnote)
• Shares owned after transaction: Not specified in this filing
• Timeliness: The Q1 (2026-03-02) RSU grant was not filed timely due to an administrative error (filing includes footnote explaining the delay)

Context RSU grants to directors as compensation are common and reflect board pay rather than an immediate personal purchase or sale. Because these are awards (not purchases), they do not necessarily signal the director’s market view. The late reporting of the March award was attributed to an administrative error; late filings are disclosure issues but do not by themselves indicate trading intent.